CLGNのチャート
CLGNの企業情報
| symbol | CLGN |
|---|---|
| 会社名 | CollPlant Holdings Ltd （コルプラント・ホ―ルディングス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Industrial Specialties |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- コルプラント・ホ―ルディングスはイスラエルの再生医薬品メ―カ―。組織や器官の3Dバイオプリンティングに注力し、人体由来・天然性の材料を用いるオ―ソバイオロジクスや先進創傷ケア市場向けの組織修復用医薬品の開発・商業化に従事する。同社製品は遺伝子工学技術における独自の組み換え体ヒトコラ―ゲンに基づく。本社所在地はネスジオナ。 CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. |
| 本社所在地 | 3 Sapir Street Weizmann Science Park Ness Ziona 74140 ISR |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 2004年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 29人 |
| url | www.collplant.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clgn |
| adr_tso | 149041 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 5.01 |
| 時価総額（marketcap） | 746695.41 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
CLGNのテクニカル分析
CLGNのニュース
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs 2023/04/04 12:26:00 Business Wire
EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)---- $SSYS #3dprinting--Stratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant''s regenerative breast implan
CollPlant GAAP EPS of -$1.53 beats by $0.03, revenue of $0.3M in-line 2023/03/29 11:06:15 Seeking Alpha
CollPlant press release (CLGN): FY GAAP EPS of -$1.53 beats by $0.03.Revenue of $0.3M (-98.1% Y/Y) in-line.Cash, cash equivalents and short-term deposits as of December 31,…
CollPlant (CLGN) Stock: Expanding End-Market Opportunities 2023/02/12 11:31:27 Seeking Alpha
CollPlant Biotechnologies is a unique biotech company anchored with AbbVie relationship. Click here to read my analysis of CLGN stock.
CollPlant Issues Letter to Shareholders 2023/01/24 12:00:00 PR Newswire
REHOVOT, Israel, Jan. 24, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive…
Can you now get a good deal on CollPlant Biotechnologies Ltd.’s shares? 2022/12/26 17:16:00 US Post News
The share price of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) fell to $8.34 per share on Friday from $8.68. While CollPlant Biotechnologies Ltd. has underperformed by -3.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLGN fell by -36.91%, with highs and lows ranging from $18.30 to $4.27, […]
CollPlant GAAP EPS of -$1.53 beats by $0.03, revenue of $0.3M in-line 2023/03/29 11:06:15 Seeking Alpha
CollPlant press release (CLGN): FY GAAP EPS of -$1.53 beats by $0.03.Revenue of $0.3M (-98.1% Y/Y) in-line.Cash, cash equivalents and short-term deposits as of December 31,…
CollPlant (CLGN) Stock: Expanding End-Market Opportunities 2023/02/12 11:31:27 Seeking Alpha
CollPlant Biotechnologies is a unique biotech company anchored with AbbVie relationship. Click here to read my analysis of CLGN stock.
CollPlant Issues Letter to Shareholders 2023/01/24 12:00:00 PR Newswire
REHOVOT, Israel, Jan. 24, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive…
Can you now get a good deal on CollPlant Biotechnologies Ltd.’s shares? 2022/12/26 17:16:00 US Post News
The share price of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) fell to $8.34 per share on Friday from $8.68. While CollPlant Biotechnologies Ltd. has underperformed by -3.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLGN fell by -36.91%, with highs and lows ranging from $18.30 to $4.27, […]
CollPlant Non-GAAP EPS of -$0.34, revenue of $0.11M 2022/12/01 12:27:55 Seeking Alpha
CollPlant press release (CLGN): Q3 Non-GAAP EPS of -$0.34.Revenue of $0.11M (-21.4% Y/Y).Cash, cash equivalents and short-term deposits as of September 30, 2022, were $33 million.
CollPlant Issues Letter to Shareholders 2023/01/24 12:00:00 PR Newswire
REHOVOT, Israel, Jan. 24, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive…
Can you now get a good deal on CollPlant Biotechnologies Ltd.’s shares? 2022/12/26 17:16:00 US Post News
The share price of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) fell to $8.34 per share on Friday from $8.68. While CollPlant Biotechnologies Ltd. has underperformed by -3.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLGN fell by -36.91%, with highs and lows ranging from $18.30 to $4.27, […]
CollPlant Non-GAAP EPS of -$0.34, revenue of $0.11M 2022/12/01 12:27:55 Seeking Alpha
CollPlant press release (CLGN): Q3 Non-GAAP EPS of -$0.34.Revenue of $0.11M (-21.4% Y/Y).Cash, cash equivalents and short-term deposits as of September 30, 2022, were $33 million.